



Amarin Corporation plc
 Investor Relations Department
 2 Pembroke House, Upper
 Pembroke
 Street 28-32
 Dublin 2
 Ireland

[Visit IR website](#)

[Sign-up for Email alerts](#)

| NASDAQ: AMRN | |
|---------------|----------------------------|
| Last Trade: | 3.97 |
| Trade Time: | 4:00 PM ET Jan 19, 2018 |
| Change: | -0.01 (-0.251%) |
| Day Range | 3.93 - 4.02 |
| 52-Week Range | 2.81 - 4.47 |
| Volume | 1,134,846 |

Stock information is provided by eSignal,
 stock charts provided by EDGAR Online.
 Stock data is delayed approximately 20
 minutes.

Company Profile

Amarin is conducting a cardiovascular outcomes study designed to evaluate the efficacy of Vascepa® in reducing cardiovascular events in a high-risk patient population on statin therapy called the REDUCE-IT trial.

Amarin is headquartered in Dublin, Ireland. Amarin's U.S. office is in Bedminster, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN").

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Jan 17, 2018
[Amarin Announces Commencement of VASCEPA® Clinical Development in Mainland China](#)
- Jan 4, 2018
[Amarin Provides Preliminary 2017 Results and Provides 2018 Outlook](#)
- Dec 19, 2017
[Amarin Announces REDUCE-IT Cardiovascular Outcomes Study Final Patient Visits to Commence in March 2018](#)
- Dec 18, 2017
[Amarin to Present at 36th Annual J.P. Morgan Healthcare Conference in San Francisco](#)
- Nov 14, 2017
[Real World Data Analysis Shows That Persistent Hypertriglyceridemia Despite Statin Therapy is Associated With Cardiovascular Risk](#)

Financials [\[View all \]](#)

- [Third Quarter Financial Results](#)
- Mar 1, 2017
[Annual Report \(10-K\)](#)
- Apr 21, 2017
[Proxy Statement \(DEF 14A\)](#)
- Nov 1, 2017
[Quarterly Report \(10-Q\)](#)
- Aug 2, 2017
[Quarterly Report \(10-Q\)](#)
- May 3, 2017
[Quarterly Report \(10-Q\)](#)